Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02079246 · ClinicalTrials.gov registry record · Phase 3
Long-term Safety and Tolerability of Idalopirdine (Lu AE58054) as Adjunctive Treatment to Donepezil in Patients With Mild-moderate Alzheimer's Disease
A Phase 3 study, sponsored by H. Lundbeck A/S.
- Completed
- Registry status
- Phase 3
- Development phase
- 1,463
- Enrollment target
NCT02079246: Completed Phase 3 study, sponsored by H. Lundbeck A/S.
NCT02079246 is a Phase 3 study that has completed, run by H. Lundbeck A/S. The registered enrollment target is 1,463 participants, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (90% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02079246, a Phase 3 study, has completed, sponsored by H. Lundbeck A/S.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1,463 participants
- Enrollment target
Study Summary
To evaluate the long-term safety and tolerability of idalopirdine (Lu AE58054) as adjunctive therapy to donepezil in patients with mild-moderate Alzheimer's Disease (AD).
Primary Outcome
A TEAE is an adverse event that starts or increases in intensity after the date of Baseline II.
Interventions
- DRUG Idalopirdine 60 mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,463 participants |
| Start Date | 2014-04-07 |
| Est. Completion | 2017-07-06 |
| Phase | Phase 3 |
What the finished NCT02079246 record still lists
NCT02079246 is an interventional study that assigns participants to a tested intervention. Its 1,463 participants enrollment target places it among the larger protocols in the corpus, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (90% higher).
The record links to 0 conditions, and to 1 intervention - of which Idalopirdine 60 mg is the first listed.
NCT02079246 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02079246 about?
NCT02079246 is a clinical study titled "Long-term Safety and Tolerability of Idalopirdine (Lu AE58054) as Adjunctive Treatment to Donepezil in Patients With Mild-moderate Alzheimer's Disease". To evaluate the long-term safety and tolerability of idalopirdine (Lu AE58054) as adjunctive therapy to donepezil in patients with mild-moderate Alzheimer's Disease (AD).
What is the current status of trial NCT02079246?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,463 participants. The study started on 2014-04-07. Estimated completion is 2017-07-06.
What interventions are being tested in trial NCT02079246?
The interventions under investigation include: Idalopirdine 60 mg (DRUG).
Who is sponsoring clinical trial NCT02079246?
This trial is sponsored by H. Lundbeck A/S, which has 72 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02079246's enrollment target sits among peer trials
1,463 164th of 2000 higher than 1,837 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03936361 · 1,456 participants · Phase 3
Statins In Intracerbral Hemorrhage
- NCT06782347 · 1,454 participants · NA
Activating SilverSneakers Benefits for Seniors With Osteoarthritis
- NCT04566328 · 1,450 participants · Phase 3
Testing the Use of Combination Therapy in Adult Patients With Newly Diagnosed Multiple Myeloma, the EQUATE Trial
- NCT05229341 · 1,450 participants · NA
Evaluation of DNA Methylation Signatures for the Diagnosis and Management of Thyroid Nodules
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI